AR112822A2 - Método con inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos - Google Patents
Método con inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojosInfo
- Publication number
- AR112822A2 AR112822A2 ARP180102672A ARP180102672A AR112822A2 AR 112822 A2 AR112822 A2 AR 112822A2 AR P180102672 A ARP180102672 A AR P180102672A AR P180102672 A ARP180102672 A AR P180102672A AR 112822 A2 AR112822 A2 AR 112822A2
- Authority
- AR
- Argentina
- Prior art keywords
- cr11r12
- alkyl
- haloalkyl
- independently selected
- nrcrd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un método para el tratamiento de un desorden de ojo seco en un paciente en necesidad del mismo, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente efectiva de un agente seleccionado entre: (a) compuestos de fórmula (1), donde: A¹ y A² se seleccionan independientemente entre C y N; T, U, y V se seleccionan independientemente entre O, S, N, CR⁵, y NR⁶; donde el anillo de 5 miembros formado por A¹, A², U, T, y V es aromático; X es N o CR⁴; Y es C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, (CR¹¹R¹²)ₚ-(C₃₋₁₀ cicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(arilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(C₁₋₁₀ heterocicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(heteroarilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚO(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)O(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜC(O)NRᵈ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)₂(CR¹¹R¹²)q, o (CR¹¹R¹²)ₚS(O)₂NRᶜ(CR¹¹R¹²)q, donde dicho C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, cicloalquileno, arileno, heterocicloalquileno, o heteroarileno, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre -D¹-D²-D³-D⁴; Z es H, halo, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, =C-Rⁱ, =N-Rⁱ, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5, ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ; donde cuando Z es H, n es 1; o la porción -(Y)ₙ-Z se toma junto con i) A² al cual la porción se encuentra unido, ii) R⁵ o R⁶ de tanto T como V, y iii) el átomo de C o N al cual el R⁵ o R⁶ de tanto T como V se encuentra unido para formar un anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros fusionado al anillo de 5 miembros formado por A¹, A², U, T, y V, donde dicho anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros se sustituye opcionalmente con 1, 2, 3, 4, ó 5 sustituyentes seleccionados independientemente entre -(W)ₘ-Q; W es C₁₋₈ alquilenilo, C₂₋₈ alquenilenilo, C₂₋₈ alquinilenilo, O, S, C(O), C(O)NRᶜ’, C(O)O, OC(O), OC(O)NRᶜ’, NRᶜ’, NRᶜ’C(O)NRᵈ’, S(O), S(O)NRᶜ’, S(O)₂, o S(O)₂NRᶜ’; Q es H, halo, CN, NO₂, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₈ haloalquilo, halosulfanilo, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₈ haloalquilo, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo se sustituye opcionalmente con 1, 2, 3 ó 4 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy², CN, NO₂, ORᵃ’, SRᵃ’, C(O)Rᵇ’, C(O)NRᶜ’Rᵈ’, C(O)ORᵃ’, OC(O)Rᵇ’, OC(O)NRᶜ’Rᵈ’, NRᶜ’Rᵈ’, NRᶜ’C(O)Rᵇ’, NRᶜ’C(O)NRᶜ’Rᵈ’, NRᶜ’C(O)ORᵃ’, S(O)Rᵇ’, S(O)NRᶜ’Rᵈ’, S(O)₂Rᵇ’, NRᶜ’S(O)₂Rᵇ’, y S(O)₂NRᶜ’Rᵈ’; Cy¹ y Cy² se seleccionan independientemente entre arilo, heteroarilo, cicloalquilo, y heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, CN, NO₂, ORᵃ’’, SRᵃ’’, C(O)Rᵇ’’, C(O)NRᶜ’’Rᵈ’’, C(O)ORᵃ’’, OC(O)Rᵇ’’, OC(O)NRᶜ’’Rᵈ’’, NRᶜ’’Rᵈ’’, NRᶜ’’C(O)Rᵇ’’, NRᶜ’’C(O)ORᵃ’’, NRᶜ’’S(O)Rᵇ’’, NRᶜ’’S(O)₂Rᵇ’’, S(O)Rᵇ’’, S(O)NRᶜ’’Rᵈ’’, S(O)₂Rᵇ’’, y S(O)₂NRᶜ’’Rᵈ’’; R¹, R², R³, y R⁴ se seleccionan independientemente entre H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO₂, OR⁷, SR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, OC(O)R⁸, OC(O)NR⁹R¹⁰, NR⁹R¹⁰, NR⁹C(O)R⁸, NRᶜC(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, NR⁹S(O)₂R⁸, y S(O)₂NR⁹R¹⁰; R⁵ es H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, CN, NO₂, OR⁷, SR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, OC(O)R⁸, OC(O)NR⁹R¹⁰, NR⁹R¹⁰, NR⁹C(O)R⁸, NR⁹C(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, NR⁹S(O)₂R⁸, o S(O)₂NR⁹R¹⁰; R⁶ es H, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, OR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, o S(O)₂NR⁹R¹⁰; R⁷ es H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R⁸ es H, C₁₋₆, alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R⁹ y R¹⁰ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆, alquilcarbonilo, arilcarbonilo, C₁₋₆ alquilsulfonilo, arilsulfonilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo; o R⁹ y R¹⁰ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros; R¹¹ y R¹² se seleccionan independientemente entre H y -E¹-E²-E³-E⁴; D¹ y E¹ se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₈ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de C₁₋₆ alquileno, C₂₋₆, alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D² y E² se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, (C₁₋₆ alquilen)ʳ-O-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-S-(C₁₋₆ alquilen)ₛ, (C₁₋₈ alquilen)ʳ-NRᵉ-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-CO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-COO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-CONRᵉ-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SO₂-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SONRᵉ-(C₁₋₆ alquilen)ₛ, y (C₁₋₆ alquilen)ʳ-NRᵉCONRᶠ-(C₁₋₆ alquilen)ₛ, donde cada uno de C₁₋₆ alquileno, C₂₋₆ alquenileno, y C₂₋₆ alquinileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D³ y E³ se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₈ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D⁴ y E⁴ se seleccionan independientemente entre H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₆ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5 ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ; Rᵃ es H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵇ es H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵃ’ y Rᵃ’’ se seleccionan independientemente entre H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵇ’ y Rᵇ’’ se seleccionan independientemente entre H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᶜ y Rᵈ se seleccionan independientemente entre H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre Cy¹, -(C₁₋₆ alquil)-Cy¹, OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, y halosulfanilo; o Rᶜ y Rᵈ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre Cy¹, -(C₁₋₆ alquil)-Cy¹, OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, y halosulfanilo; Rᶜ’ y Rᵈ’ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; o Rᶜ’ y Rᵈ’ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᶜ’’ y Rᵈ’’ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₁₀ alquilo, C₁₋₈ haloalquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, C₁₋₆ haloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; o Rᶜ’’ y Rᵈ’’ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rⁱ es H, CN, NO₂, o C₁₋₆ alquilo; Rᵉ y Rᶠ se seleccionan independientemente entre H y C₁₋₆ alquilo; Rⁱ es H, CN, o NO₂; m es 0 ó 1; n es 0 ó 1; p es 0, 1, 2, 3, 4, 5 ó 6; q es 0, 1, 2, 3, 4, 5 ó 6; r es 0 ó 1; y s es 0 ó 1; donde cuando X es N, n es 1, y la porción formada por A¹, A², U, T, V, y -(Y)ₙ-Z tiene la fórmula (4); luego Y es diferente de (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q; (b) compuestos de fórmula (2), donde: Lᵃ es SO₂ o CO; R¹ᵃ es C₁₋₆ alquilo, C₃₋₇ cicloalquilo, fenilo, heteroarilo de 5 ó 6 miembros, indolilo, NR²ᵃR³ᵃ, o OR⁴ᵃ, donde dicho alquilo, cicloalquilo, fenilo, o heteroarilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre F, CN, y C₁₋₄ alquilo; R²ᵃ y R³ᵃ se seleccionan independientemente entre H, C₁₋₄ alquilo, y fenilo; y R⁴ᵃ es C₁₋₆ alquilo, fenilo, o bencilo; (c) compuestos de fórmula (3), donde: R⁵ᵃ y R⁶ᵃ se seleccionan independientemente entre H, F, CN, OH, C₁₋₄ alquilo, benciloxi, C₂₋₆ dialquilaminosulfonilo, y heteroarilo de 5 miembros, donde dicho alquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados entre F, OH, CN, y C₁₋₄ alcoxi, y donde dicho heteroarilo de 5 miembros se sustituye opcionalmente con C₁₋₄ alquilo; y sales aceptables farmacéuticamente del mismo; siempre que el compuesto de fórmula (1) no se seleccione entre 4-[5-(2-isopropil-5-metilciclohexiloximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(4-tert-butilfenoximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-ciclopentiletil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(2,6-difluorofenil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(1-tert-butil-3-metil-1H-pirazol-5-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(benciloximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(3-fluorofenil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(fenoximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(4-metoxibencil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(feniltiometil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(3-metilbutil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-bencil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(2,2-dimetilpropil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-metil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(formil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(furan-2-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(1-metil-1H-pirrol-2-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(sec-butil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-ciclopropil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; y sales aceptables farmacéuticamente de cualquiera de los precedentes. Reivindicación 18: Un método de acuerdo con la reivindicación 17, caracterizado porque dicho agente terapéutico adicional es acetónido de fluocinolona, rimexolona, ciclosporina, riaminolona, dexametasona, fluocinolona, cortisona, prednisolona, flumetolona, civamida, testosterona, ecabet de sodio, ácido 15-(s)-hidroxieicosatetraenoico, (2S,3S,4R,5R)-3,4-dihidroxi-5-[6-[(3-iodofenil)metilamino]purin-9-il]-N-metil-oxolan-2-carboxamida, gefarnato, cevilemina, doxiclina, minociclina, oxitetraciclina, voclosporina, rivoglitazona, lacritin rebamipida, pilocarpina, tacrolimus, pimecrolimus, loteprednol etabonato, rituximab, diquafosol tetrasódico, dehidroepiandrosterona, anakinra, efalizumab, micofenolato de sodio, etanercept, hidroxicloroquina o talidomida. Reivindicación 51: Un equipo para el tratamiento de desórdenes de ojo seco, que comprende una composición oftálmica o farmacéutica e instrucciones; caracterizado porque dicha composición comprende una cantidad terapéuticamente efectiva de un agente seleccionado entre: (a) compuestos de fórmula (1), donde: A¹ y A² se seleccionan independientemente entre C y N; T, U, y V se seleccionan independientemente entre O, S, N, CR⁵, y NR⁶; donde el anillo de 5 miembros formado por A¹, A², U, T, y V es aromático; X es N o CR⁴; Y es C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, (CR¹¹R¹²)ₚ-(C₃₋₁₀ cicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(arilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(C₁₋₁₀ heterocicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(heteroarilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚO(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)O(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜC(O)NRᵈ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)₂(CR¹¹R¹²)q, o (CR¹¹R¹²)ₚS(O)₂NRᶜ(CR¹¹R¹²)q, donde dicho C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, cicloalquileno, arileno, heterocicloalquileno, o heteroarileno, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre -D¹-D²-D³-D⁴; Z es H, halo, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, =C-Rⁱ, =N-Rⁱ, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5, ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10224208P | 2008-10-02 | 2008-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112822A2 true AR112822A2 (es) | 2019-12-18 |
Family
ID=41572626
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103822A AR073530A1 (es) | 2008-10-02 | 2009-10-02 | Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico |
ARP180102672A AR112822A2 (es) | 2008-10-02 | 2018-09-19 | Método con inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103822A AR073530A1 (es) | 2008-10-02 | 2009-10-02 | Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico |
Country Status (19)
Country | Link |
---|---|
US (4) | US20100113416A1 (es) |
EP (2) | EP2349260B1 (es) |
JP (5) | JP2012504639A (es) |
AR (2) | AR073530A1 (es) |
CA (2) | CA2738520C (es) |
CL (1) | CL2009001884A1 (es) |
CY (1) | CY1117317T1 (es) |
DK (1) | DK2349260T3 (es) |
ES (1) | ES2564203T3 (es) |
HK (1) | HK1160607A1 (es) |
HR (1) | HRP20160330T1 (es) |
HU (1) | HUE028499T2 (es) |
PL (1) | PL2349260T3 (es) |
PT (1) | PT2349260E (es) |
RS (1) | RS54651B1 (es) |
SI (1) | SI2349260T1 (es) |
SM (1) | SMT201600080B (es) |
TW (2) | TWI591068B (es) |
WO (1) | WO2010039939A1 (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
DK2455382T3 (da) | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer |
WO2008015018A1 (en) | 2006-08-03 | 2008-02-07 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
EP2101819B1 (en) | 2006-11-20 | 2013-01-09 | President and Fellows of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
PT3070090T (pt) | 2007-06-13 | 2019-03-20 | Incyte Holdings Corp | Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo |
CA2704599C (en) * | 2007-11-16 | 2015-05-12 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
AU2010207740B2 (en) * | 2009-01-26 | 2016-06-16 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
CA2761954C (en) | 2009-05-22 | 2018-07-31 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CA3027255C (en) | 2009-07-10 | 2022-06-21 | The General Hospital Corporation | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102596960B (zh) * | 2009-10-09 | 2016-01-20 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
AR078675A1 (es) | 2009-10-20 | 2011-11-23 | Cellzome Ltd | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. |
SG183551A1 (en) * | 2010-03-10 | 2012-10-30 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
KR20130094693A (ko) | 2010-04-30 | 2013-08-26 | 셀좀 리미티드 | Jak 저해제로서의 피라졸 화합물 |
SG185567A1 (en) | 2010-05-21 | 2012-12-28 | Incyte Corp | Topical formulation for a jak inhibitor |
AU2011258005A1 (en) * | 2010-05-28 | 2013-01-17 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as Janus kinase inhibitors |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
UA113156C2 (xx) | 2010-11-19 | 2016-12-26 | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
KR102024948B1 (ko) | 2011-02-18 | 2019-11-04 | 노파르티스 파르마 아게 | mTOR/JAK 저해제 병용 요법 |
US9115133B2 (en) | 2011-03-22 | 2015-08-25 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
EP2729466B1 (en) | 2011-07-08 | 2015-08-19 | Novartis AG | Novel pyrrolo pyrimidine derivatives |
CN103781780B (zh) | 2011-07-28 | 2015-11-25 | 赛尔佐姆有限公司 | 作为jak抑制剂的杂环基嘧啶类似物 |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
RU2014115476A (ru) | 2011-09-20 | 2015-10-27 | Целльзом Лимитед | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ |
CA2851801A1 (en) * | 2011-10-21 | 2013-04-25 | Glaxosmithkline Llc | Compounds and methods for enhancing innate immune responses |
JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−2,4−ジアミン誘導体 |
WO2013108644A1 (ja) * | 2012-01-20 | 2013-07-25 | 京都府公立大学法人 | レバミピドのアレルギー性結膜炎治療剤 |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
EP2855451B1 (en) | 2012-05-24 | 2017-10-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
EP2917221A1 (en) | 2012-11-01 | 2015-09-16 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
EP2919766B1 (en) | 2012-11-15 | 2021-05-26 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
UA121532C2 (uk) | 2013-03-06 | 2020-06-10 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
EP3786162B1 (en) | 2013-05-17 | 2023-08-09 | Incyte Holdings Corporation | Bipyrazole derivatives as jak inhibitors |
US9655854B2 (en) * | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9289494B2 (en) * | 2013-11-20 | 2016-03-22 | RestorTears, LLC | Method of treating ocular disorders with compounds found in Harderian gland secretions |
RS61058B1 (sr) | 2014-04-08 | 2020-12-31 | Incyte Corp | Lečenje b-ćelijskih maligniteta sa kombinacijom inhibitora jak i pi3k |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
CN105924444B (zh) * | 2015-03-11 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | Jak抑制剂的晶型及其制备方法 |
RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
CN106554363B (zh) * | 2015-09-28 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 一种Baricitinib中间体的制备方法 |
MY195427A (en) | 2015-11-03 | 2023-01-20 | Theravance Biopharma R&D Ip Llc | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease |
DK3360878T3 (da) | 2015-12-11 | 2020-11-09 | Sichuan Kelun Biotech Biopharmaceutica Co Ltd | Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
CN108699063B (zh) * | 2015-12-31 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 一种芦可替尼的合成工艺 |
CN107573348B (zh) * | 2016-01-29 | 2019-09-03 | 上海宣创生物科技有限公司 | 巴瑞克替尼三氟乙酸盐b晶型及其制备方法 |
CN105601635B (zh) * | 2016-02-01 | 2017-12-12 | 上海宣创生物科技有限公司 | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 |
CN107200742A (zh) * | 2016-03-18 | 2017-09-26 | 罗欣生物科技(上海)有限公司 | 一种巴瑞克替尼磷酸盐晶体及其制备方法 |
CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
EP3504213A4 (en) | 2016-08-24 | 2020-01-15 | ArQule, Inc. | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE |
AU2017324262B2 (en) * | 2016-09-07 | 2023-06-22 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
WO2018056268A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | 炎症性眼疾患の治療及び/又は予防剤 |
WO2018056269A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | Jak阻害剤を含有する点眼剤 |
CZ2016816A3 (cs) | 2016-12-21 | 2018-07-04 | Zentiva, K.S. | Krystalické formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a způsob jejich přípravy |
AU2018209579B2 (en) | 2017-01-23 | 2020-12-24 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | JAK kinase inhibitor and preparation method and use thereof |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
WO2018189335A1 (en) | 2017-04-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
CN110494435B (zh) * | 2017-06-07 | 2022-02-15 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物的固体形式及其制备方法和用途 |
US10759865B2 (en) * | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
US10800775B2 (en) * | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS FOR THEIR MANUFACTURE AND USE |
CN109867675B (zh) * | 2017-12-01 | 2021-01-19 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
CA3091339A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
IL302865A (en) | 2018-03-30 | 2023-07-01 | Incyte Corp | Use of JAK inhibitors to treat hidradenitis suppurativa |
WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
US11372003B2 (en) | 2018-04-13 | 2022-06-28 | Incyte Corporation | Biomarkers for graft-versus-host disease |
JP2021534244A (ja) | 2018-08-10 | 2021-12-09 | アクラリス セラピューティクス,インコーポレイテッド | ピロロピリミジンitk阻害剤 |
CN113164384A (zh) | 2018-10-26 | 2021-07-23 | 维拉莫有限公司 | 黏膜粘附性凝胶组合物 |
WO2020092726A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
WO2020173364A1 (zh) * | 2019-02-27 | 2020-09-03 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
KR20210143791A (ko) | 2019-03-11 | 2021-11-29 | 녹시온 테라퓨틱스 인코포레이티드 | 하전된 이온 채널 차단제 및 사용 방법 |
KR20210145164A (ko) | 2019-03-11 | 2021-12-01 | 녹시온 테라퓨틱스 인코포레이티드 | 에스테르 치환된 이온 채널 차단제 및 사용 방법 |
MA55311A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques chargés et procédés d'utilisation |
MX2021013224A (es) | 2019-05-02 | 2022-01-06 | Aclaris Therapeutics Inc | Pirrolopiridinas sustituidas como inhibidores de jak. |
CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
BR112022009710A2 (pt) | 2019-11-22 | 2022-08-09 | Incyte Corp | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
EP4118070A4 (en) | 2020-03-11 | 2024-04-10 | Nocion Therapeutics Inc | CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE |
MX2022015221A (es) | 2020-06-02 | 2023-03-08 | Incyte Corp | Procesos para preparar un inhibidor de cinasa jano 1 (jak1). |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
AU2021329301A1 (en) | 2020-08-18 | 2023-04-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
CN114085224A (zh) * | 2020-08-25 | 2022-02-25 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶化合物的制备方法 |
KR20230118118A (ko) | 2020-12-08 | 2023-08-10 | 인사이트 코포레이션 | 백반증의 치료를 위한 jak1 경로 저해제 |
CN114907354B (zh) * | 2021-02-07 | 2024-04-09 | 南京知和医药科技有限公司 | 一种磺酰胺类多环化合物及其制备方法与用途 |
CN114957260B (zh) * | 2021-02-26 | 2024-04-09 | 南京知和医药科技有限公司 | 一种巴瑞替尼衍生物及其制备方法与用途 |
WO2023100918A1 (ja) * | 2021-11-30 | 2023-06-08 | 興和株式会社 | 新規ニコチンアミド化合物及びその用途 |
WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US5919779A (en) * | 1997-08-11 | 1999-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
AU2001274598A1 (en) * | 2000-06-23 | 2002-01-02 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
US20040077654A1 (en) * | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
CA2446864C (en) * | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
WO2003011285A1 (en) * | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
KR20040058340A (ko) * | 2001-11-30 | 2004-07-03 | 데이진 가부시키가이샤 | 5-(3-시아노페닐)-3-포르밀벤조산 화합물의 제조 방법 |
US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
WO2003094888A1 (en) * | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
CA2486183C (en) * | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
BR0314603A (pt) * | 2002-09-20 | 2005-07-26 | Alcon Inc | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos |
US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UY28126A1 (es) * | 2002-12-24 | 2004-06-30 | Alcon Inc | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular |
EP1611125A1 (en) * | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7183941B2 (en) * | 2003-07-30 | 2007-02-27 | Lear Corporation | Bus-based appliance remote control |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
CN1870997B (zh) * | 2003-10-24 | 2011-05-04 | 参天制药株式会社 | 角膜结膜病变的治疗剂 |
TW200528450A (en) * | 2003-12-19 | 2005-09-01 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
US20050165029A1 (en) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
JP5315611B2 (ja) * | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
DE102004038530B3 (de) * | 2004-08-07 | 2006-01-05 | Universität Mannheim | Verfahren und Vorrichtung zur Herstellung einer optischen Verbindung zwischen einem optoelektronischen Bauelement und einem Lichtwellenleiter |
PT1802625E (pt) * | 2004-10-13 | 2008-08-06 | Hoffmann La Roche | Pirazolobenzodiazepinas di-substituídas, úteis como inibidores de cdc2 e de angiogénese e para o tratamento de cancro da mama, do cólon, do pulmão e da próstata |
US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2006065916A1 (en) * | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
MX2007009429A (es) * | 2005-02-03 | 2008-03-18 | Vertex Pharma | Pirrolopirimidinas utiles como inhibidores de proteinas cinasas. |
US8921376B2 (en) * | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
KR101312225B1 (ko) * | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
EP1926735A1 (en) * | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
BR122021011787B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
WO2007062459A1 (en) * | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
DK2455382T3 (da) * | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer |
CA2634787C (en) * | 2005-12-23 | 2014-10-21 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
EP1979353A2 (en) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
WO2007090141A2 (en) * | 2006-02-01 | 2007-08-09 | Smithkline Beecham Corporation | Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors |
BRPI0708731A2 (pt) * | 2006-03-10 | 2011-06-07 | Ono Pharmaceutical Co | derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo |
BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
US8741912B2 (en) * | 2006-04-05 | 2014-06-03 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of Janus kinases |
US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
WO2008016123A1 (fr) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
ATE517868T1 (de) * | 2006-08-16 | 2011-08-15 | Boehringer Ingelheim Int | Pyrazinverbindungen, ihre verwendung und herstellungsverfahren |
AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
JP5357763B2 (ja) * | 2006-11-06 | 2013-12-04 | トレロ ファーマシューティカルズ, インコーポレイテッド | イミダゾ[1,2−b]ピリダジン誘導体およびピラゾロ[1,5−a]ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 |
US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
EP2103061A2 (en) * | 2006-12-05 | 2009-09-23 | Myriad Group AG | System and method of providing access to instant messaging services via a wireless network |
EP2109364A4 (en) * | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
CA2672903C (en) * | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
WO2008079965A1 (en) * | 2006-12-22 | 2008-07-03 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
RU2445098C2 (ru) * | 2007-07-11 | 2012-03-20 | Пфайзер Инк. | Фармацевтические композиции и способы лечения сухих кератитов |
AU2008281543A1 (en) * | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as Raf inhibitors |
WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
JP5485172B2 (ja) * | 2008-01-18 | 2014-05-07 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック | 新規な細胞増殖抑制性7−デアザプリンヌクレオシド |
EA017218B1 (ru) * | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
CA2761954C (en) * | 2009-05-22 | 2018-07-31 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
NZ596479A (en) * | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102596960B (zh) * | 2009-10-09 | 2016-01-20 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
EA023444B1 (ru) * | 2010-02-18 | 2016-06-30 | Инсайт Холдингс Корпорейшн | Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения |
SG183551A1 (en) * | 2010-03-10 | 2012-10-30 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
-
2009
- 2009-09-23 CL CL2009001884A patent/CL2009001884A1/es unknown
- 2009-10-01 EP EP09737257.7A patent/EP2349260B1/en active Active
- 2009-10-01 CA CA2738520A patent/CA2738520C/en active Active
- 2009-10-01 TW TW098133430A patent/TWI591068B/zh active
- 2009-10-01 RS RS20160064A patent/RS54651B1/en unknown
- 2009-10-01 WO PCT/US2009/059203 patent/WO2010039939A1/en active Application Filing
- 2009-10-01 HU HUE09737257A patent/HUE028499T2/en unknown
- 2009-10-01 DK DK09737257.7T patent/DK2349260T3/en active
- 2009-10-01 EP EP15195683.6A patent/EP3042655A1/en not_active Withdrawn
- 2009-10-01 CA CA3064247A patent/CA3064247A1/en not_active Abandoned
- 2009-10-01 ES ES09737257.7T patent/ES2564203T3/es active Active
- 2009-10-01 TW TW106111786A patent/TWI643622B/zh active
- 2009-10-01 PL PL09737257T patent/PL2349260T3/pl unknown
- 2009-10-01 PT PT97372577T patent/PT2349260E/pt unknown
- 2009-10-01 US US12/571,834 patent/US20100113416A1/en not_active Abandoned
- 2009-10-01 SI SI200931388A patent/SI2349260T1/sl unknown
- 2009-10-01 JP JP2011530218A patent/JP2012504639A/ja not_active Withdrawn
- 2009-10-02 AR ARP090103822A patent/AR073530A1/es not_active Application Discontinuation
-
2012
- 2012-02-02 HK HK12101002.0A patent/HK1160607A1/zh unknown
- 2012-08-01 US US13/564,271 patent/US20120301464A1/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015042933A patent/JP2015127332A/ja active Pending
-
2016
- 2016-03-22 CY CY20161100241T patent/CY1117317T1/el unknown
- 2016-03-22 SM SM201600080T patent/SMT201600080B/it unknown
- 2016-04-01 HR HRP20160330TT patent/HRP20160330T1/hr unknown
- 2016-05-16 US US15/156,125 patent/US20170087158A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000685A patent/JP2017057231A/ja active Pending
- 2017-12-22 JP JP2017246134A patent/JP2018044012A/ja active Pending
-
2018
- 2018-09-19 AR ARP180102672A patent/AR112822A2/es unknown
-
2019
- 2019-11-18 US US16/686,934 patent/US20200093825A1/en not_active Abandoned
-
2020
- 2020-01-09 JP JP2020002245A patent/JP2020050682A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201018689A (en) | 2010-05-16 |
HRP20160330T1 (hr) | 2016-05-06 |
JP2015127332A (ja) | 2015-07-09 |
PL2349260T3 (pl) | 2016-07-29 |
JP2018044012A (ja) | 2018-03-22 |
TWI643622B (zh) | 2018-12-11 |
DK2349260T3 (en) | 2016-01-25 |
HUE028499T2 (en) | 2016-12-28 |
CA2738520A1 (en) | 2010-04-08 |
EP3042655A1 (en) | 2016-07-13 |
TW201801731A (zh) | 2018-01-16 |
US20170087158A1 (en) | 2017-03-30 |
SMT201600080B (it) | 2016-07-01 |
EP2349260A1 (en) | 2011-08-03 |
CY1117317T1 (el) | 2017-04-26 |
HK1160607A1 (zh) | 2012-08-10 |
US20200093825A1 (en) | 2020-03-26 |
SI2349260T1 (sl) | 2016-05-31 |
CL2009001884A1 (es) | 2010-05-14 |
US20100113416A1 (en) | 2010-05-06 |
JP2020050682A (ja) | 2020-04-02 |
JP2012504639A (ja) | 2012-02-23 |
TWI591068B (zh) | 2017-07-11 |
WO2010039939A1 (en) | 2010-04-08 |
EP2349260B1 (en) | 2016-01-06 |
RS54651B1 (en) | 2016-08-31 |
ES2564203T3 (es) | 2016-03-18 |
PT2349260E (pt) | 2016-03-07 |
CA2738520C (en) | 2020-03-10 |
JP2017057231A (ja) | 2017-03-23 |
US20120301464A1 (en) | 2012-11-29 |
AR073530A1 (es) | 2010-11-10 |
CA3064247A1 (en) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112822A2 (es) | Método con inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos | |
ES2320955B1 (es) | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. | |
JP5934403B2 (ja) | 5,6−ジヒドロ−1h−ピリジン−2−オン化合物 | |
ES2857687T3 (es) | Piridona amidas como moduladores de los canales de sodio | |
AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
JP2009520685A5 (es) | ||
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
JP2013503903A5 (es) | ||
AR054090A1 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion | |
AR113820A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
AR031556A1 (es) | Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden | |
RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
ES2702477T3 (es) | Compuestos (hetero) aromáticos bicíclicos fusionados útiles para el tratamiento de cánceres | |
AR064345A1 (es) | Derivados de 8-oxoadenina | |
AR057959A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
PE20040974A1 (es) | Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que los contienen y procedimientos para su preparacion | |
AR067569A1 (es) | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr 119 y compuestos seleccionados | |
RU2009102535A (ru) | Производные карбамидов тропана, их получение и их применение в терапии | |
RU2008126807A (ru) | Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов | |
AR049664A1 (es) | Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits. | |
AR081139A1 (es) | Uracilos herbicidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |